AU2020277881B2 - Crystalline form of sofpironium bromide and preparation method thereof - Google Patents

Crystalline form of sofpironium bromide and preparation method thereof Download PDF

Info

Publication number
AU2020277881B2
AU2020277881B2 AU2020277881A AU2020277881A AU2020277881B2 AU 2020277881 B2 AU2020277881 B2 AU 2020277881B2 AU 2020277881 A AU2020277881 A AU 2020277881A AU 2020277881 A AU2020277881 A AU 2020277881A AU 2020277881 B2 AU2020277881 B2 AU 2020277881B2
Authority
AU
Australia
Prior art keywords
theta
compound
crystalline form
crystal form
content
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020277881A
Other languages
English (en)
Other versions
AU2020277881A1 (en
Inventor
Herbert R. Brinkman
Kazuyoshi Marubayashi
Masahito Watanabe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kaken Pharmaceutical Co Ltd
Fresh Tracks Therapeutics Inc
Original Assignee
Kaken Pharmaceutical Co Ltd
Brickell Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kaken Pharmaceutical Co Ltd, Brickell Biotech Inc filed Critical Kaken Pharmaceutical Co Ltd
Publication of AU2020277881A1 publication Critical patent/AU2020277881A1/en
Application granted granted Critical
Publication of AU2020277881B2 publication Critical patent/AU2020277881B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/147—Saturated compounds having only one carboxyl group and containing —CHO groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pyrrole Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU2020277881A 2019-05-23 2020-05-22 Crystalline form of sofpironium bromide and preparation method thereof Active AU2020277881B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962851880P 2019-05-23 2019-05-23
US62/851,880 2019-05-23
PCT/JP2020/020210 WO2020235665A1 (en) 2019-05-23 2020-05-22 Crystalline form of sofpironium bromide and preparation method thereof

Publications (2)

Publication Number Publication Date
AU2020277881A1 AU2020277881A1 (en) 2021-12-09
AU2020277881B2 true AU2020277881B2 (en) 2025-03-06

Family

ID=72146250

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020277881A Active AU2020277881B2 (en) 2019-05-23 2020-05-22 Crystalline form of sofpironium bromide and preparation method thereof

Country Status (18)

Country Link
US (3) US20220298108A1 (https=)
EP (1) EP3972955A4 (https=)
JP (2) JP6748329B1 (https=)
KR (1) KR20220011671A (https=)
CN (1) CN114008023B (https=)
AU (1) AU2020277881B2 (https=)
BR (1) BR112021023241A2 (https=)
CA (1) CA3139948A1 (https=)
CL (1) CL2021003047A1 (https=)
CO (1) CO2021017456A2 (https=)
IL (1) IL288285B1 (https=)
MX (1) MX2021014163A (https=)
MY (1) MY206154A (https=)
PH (1) PH12021552915A1 (https=)
SG (1) SG11202111678WA (https=)
TW (2) TWI838531B (https=)
WO (1) WO2020235665A1 (https=)
ZA (1) ZA202109514B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220298108A1 (en) * 2019-05-23 2022-09-22 Kaken Pharmaceutical Co., Ltd. Crystalline form of sofpironium bromide and preparation method thereof
EP4213158A1 (en) 2020-11-13 2023-07-19 Ahead Biocomputing, Co. Ltd Information processing device, information processing method, recording medium recording information processing program, and information processing system
CN115925603B (zh) * 2022-11-29 2025-07-22 山东齐都药业有限公司 索吡溴铵的制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007059021A1 (en) * 2005-11-10 2007-05-24 Bodor Nicholas S Soft anticholinergic zwitterions
WO2018026869A1 (en) * 2016-08-02 2018-02-08 Dermira, Inc. Processes for making, and methods of using, glycopyrronium compounds

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7927613B2 (en) * 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
ATE529399T1 (de) * 2005-11-10 2011-11-15 Nicholas S Bodor Sanfte anticholinerge ester
MX357741B (es) * 2012-07-06 2018-07-23 Laboratorios Senosiain S A De C V Star Nuevas formas sólidas de inhibidores de fosfodiesterasa tipo 5.
US9512166B2 (en) * 2012-09-05 2016-12-06 Amri Ssci, Llc Cocrystals of progesterone
US20150259283A1 (en) * 2014-03-13 2015-09-17 Brickell Biotech, Inc. Formulation for soft anticholinergic analogs
US10282282B2 (en) * 2016-06-29 2019-05-07 Synopsys, Inc. Automated HTTP user flows simulator
US20220298108A1 (en) * 2019-05-23 2022-09-22 Kaken Pharmaceutical Co., Ltd. Crystalline form of sofpironium bromide and preparation method thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007059021A1 (en) * 2005-11-10 2007-05-24 Bodor Nicholas S Soft anticholinergic zwitterions
WO2018026869A1 (en) * 2016-08-02 2018-02-08 Dermira, Inc. Processes for making, and methods of using, glycopyrronium compounds

Also Published As

Publication number Publication date
JP2020189856A (ja) 2020-11-26
IL288285B1 (en) 2026-02-01
TW202110796A (zh) 2021-03-16
CA3139948A1 (en) 2020-11-26
SG11202111678WA (en) 2021-11-29
US20210395197A1 (en) 2021-12-23
JP2020189839A (ja) 2020-11-26
AU2020277881A1 (en) 2021-12-09
CN114008023A (zh) 2022-02-01
ZA202109514B (en) 2023-12-20
US11566000B2 (en) 2023-01-31
CL2021003047A1 (es) 2022-09-20
CO2021017456A2 (es) 2022-01-17
US11584715B2 (en) 2023-02-21
EP3972955A4 (en) 2023-07-05
TW202411205A (zh) 2024-03-16
KR20220011671A (ko) 2022-01-28
CN114008023B (zh) 2024-02-09
IL288285A (en) 2022-01-01
BR112021023241A2 (pt) 2022-01-04
TWI870116B (zh) 2025-01-11
MX2021014163A (es) 2022-01-04
JP6748329B1 (ja) 2020-08-26
TWI838531B (zh) 2024-04-11
EP3972955A1 (en) 2022-03-30
JP7605598B2 (ja) 2024-12-24
US20220298108A1 (en) 2022-09-22
PH12021552915A1 (en) 2022-04-04
MY206154A (en) 2024-12-02
WO2020235665A1 (en) 2020-11-26
US20210171460A1 (en) 2021-06-10

Similar Documents

Publication Publication Date Title
AU2020277881B2 (en) Crystalline form of sofpironium bromide and preparation method thereof
EP4043455A1 (en) Bicyclic compound that acts as crbn protein regulator
CN114302883B (zh) Vmat2抑制剂及其制备方法和应用
KR20040008175A (ko) 5,8,14-트리아자테트라시클로(10.3.1.02,11.04,9)-헥사데카-2(11),3,5,7,9-펜타엔의 시트르산염 및 그의 제약 조성물
WO2022063297A1 (zh) 喹唑啉衍生物及其制备方法和用途
AU2023325622A1 (en) Crystal form of pyrazolopyrimidine ester compound and preparation method therefor
RU2686675C1 (ru) Таксановые соединения, а также способ их получения и их применения
JP7434273B2 (ja) アゼチジン誘導体のボレート
HK40068368A (en) Crystalline form of sofpironium bromide and preparation method thereof
HK40068368B (zh) 索吡溴铵的晶型及其制备方法
CN114341155A (zh) 一种肽酰胺类化合物及其中间体的制备方法
CN112638907A (zh) 一种阿片样物质受体(mor)激动剂的结晶形式及制备方法
KR20250084188A (ko) (2s,5r)-5-(2-클로로페닐)-1-(2'-메톡시-[1,1'-비페닐]-4-카르보닐)피롤리딘-2-카르복실산의다형체 및 이의 제조 방법
CN121930164A (zh) 一种乌利沙卡他胺新晶型及其制备方法
CA3246483A1 (en) Crystal form of a fused ring derivative, a prepartion method therefor and use thereof
US8569289B2 (en) Fumarate salt of 4-bromophenyl 1,4-diazabicyclo[3.2.2]nonane-4-carboxylate, crystalline forms thereof, preparation thereof and therapeutic use thereof
KR20240125023A (ko) 결정질 중간체
EP4703357A1 (en) Triazolyl-containing compounds
HK40022836B (zh) 作为wee1抑制剂的大环类化合物及其应用

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)